Regent Pacific Group (or the “Group”) is a Hong Kong based biopharmaceutical and investment company, whose shares are listed on the main board of the Hong Kong Stock Exchange (stock code: 575).
The Group has two, 100% owned proprietary products:
China and the broader Greater China region remain central to the Group’s near-term strategy through the approval of Senstend™ by the NMPA in China. The NDA for its innovative therapy, Senstend™, was recently approved by the NMPA, inclusive of a 4-year data protection period on 10 June 2026. This approval represents a major inflection point for the Company marking its successful transition into a commercial-stage biopharmaceutical leader. Senstend™ is indicated for the treatment of premature ejaculation, addressing a significant unmet medical need in the PRC and offers one of only two drugs now approved by the NMPA for the treatment of premature ejaculation, a compelling new therapeutic option for patients. The Group expects to receive a total of US$7 million (before deduction of PRC withholding tax) in 2026 from two milestone payments from Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. (“Wanbang Biopharmaceutical”) as the NDA approval triggers the payment of US$5 million (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical. Wanbang Biopharmaceutical anticipates commercial sales to commence in the second half of 2026 and this will trigger a payment of US$2 million (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical.
The Group is excited about the future potential of Senstend™ where the drug has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, growing to over 170 million patients by its tenth year. We have a strong commercial partner in Wanbang Biopharmaceutical, who has the necessary sales and marketing expertise, established e-commerce platforms and an unrivalled national distribution network of hospitals, clinics and pharmacies to help ensure the commercial success of Senstend™ in China.
2025 was a foundational year for Deep Longevity as we expanded geographically, strengthened our commercial and technical capabilities, and advanced our product suite towards greater scalability and differentiation. We launched into new markets, enhanced our core biological age prediction platform, broadened language and regional support, and made meaningful progress toward next-generation AI-based aging clocks, including Face Age and Biometric Age.
While the longevity industry continues to evolve and adoption remains uneven across segments, we believe Deep Longevity has strengthened its technological leadership, expanded its commercial pipeline, and positioned itself for accelerated growth in 2026, particularly in the US and emerging markets such as Thailand.
Our mission at Deep Longevity remains as one to revolutionise the journey of longevity by providing advanced, scientifically backed reliable ageing clocks and preventative health solutions. The market is massive, worth over US$6 trillion, and our AI enabled technology provides entry into this large and growing longevity and global wellness market.
The Group has two, 100% owned proprietary products:
- Fortacin™ (or Senstend™ in China), an approved treatment for premature ejaculation; and
- Deep Longevity, an AI digital health company, focussed on longevity, health and wellness through its AI powered ageing clocks that predict biological and psychological age.
China and the broader Greater China region remain central to the Group’s near-term strategy through the approval of Senstend™ by the NMPA in China. The NDA for its innovative therapy, Senstend™, was recently approved by the NMPA, inclusive of a 4-year data protection period on 10 June 2026. This approval represents a major inflection point for the Company marking its successful transition into a commercial-stage biopharmaceutical leader. Senstend™ is indicated for the treatment of premature ejaculation, addressing a significant unmet medical need in the PRC and offers one of only two drugs now approved by the NMPA for the treatment of premature ejaculation, a compelling new therapeutic option for patients. The Group expects to receive a total of US$7 million (before deduction of PRC withholding tax) in 2026 from two milestone payments from Jiangsu Wanbang Biopharmaceutical Group Co., Ltd. (“Wanbang Biopharmaceutical”) as the NDA approval triggers the payment of US$5 million (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical. Wanbang Biopharmaceutical anticipates commercial sales to commence in the second half of 2026 and this will trigger a payment of US$2 million (before deduction of PRC withholding tax) to the Group from Wanbang Biopharmaceutical.
The Group is excited about the future potential of Senstend™ where the drug has the potential to help an initial target market of approximately 9 million patients in China in its first year of launch, growing to over 170 million patients by its tenth year. We have a strong commercial partner in Wanbang Biopharmaceutical, who has the necessary sales and marketing expertise, established e-commerce platforms and an unrivalled national distribution network of hospitals, clinics and pharmacies to help ensure the commercial success of Senstend™ in China.
2025 was a foundational year for Deep Longevity as we expanded geographically, strengthened our commercial and technical capabilities, and advanced our product suite towards greater scalability and differentiation. We launched into new markets, enhanced our core biological age prediction platform, broadened language and regional support, and made meaningful progress toward next-generation AI-based aging clocks, including Face Age and Biometric Age.
While the longevity industry continues to evolve and adoption remains uneven across segments, we believe Deep Longevity has strengthened its technological leadership, expanded its commercial pipeline, and positioned itself for accelerated growth in 2026, particularly in the US and emerging markets such as Thailand.
Our mission at Deep Longevity remains as one to revolutionise the journey of longevity by providing advanced, scientifically backed reliable ageing clocks and preventative health solutions. The market is massive, worth over US$6 trillion, and our AI enabled technology provides entry into this large and growing longevity and global wellness market.